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Clinics and pathology 
Disease 
Myelodysplastic syndrome (MDS) in most cases, acute 
lymphoblastic leukemia (ALL) in one case. 
Phenotype/cell stem origin 
At least 3 of the 6 available cases were treatment 
related myelodysplastic syndromes (t-MDS) (Roulston 
et al., 1998; Mauritzson et al., 2002; Masuya et al., 
2002), and 2 other cases were MDS (Horiike et al., 
1988; Storlazzi et al., 2008). 
Clinics 
A 38-year-old male patient presented with a treatment 
related myelodysplastic syndrome (t-MDS) evolving 
towards an acute myeloid leukemia (t-AML). Previous 
treatment included topoisomerase inhibitors for a 
Hodgkin disease 36 months before diagnosis of the t-
MDS (Roulston et al., 1998). A t-MDS was diagnosed 
in a 76-year-old female patient previously treated with 
radiotherapy for uterine cancer 29 years ago. She died 
26 months after diagnosis of the t-MDS (Mauritzson et 
al., 2002). A 49-year-old female patient was diagnosed 
with t-MDS (FAB refractory anemia (RA)); she had 
been treated with etoposide 2 years previously for M1-
AML; the patient died 6.5 years after onset of the 
t(1;2). Other chromosome anomalies appeared during 
course of the disease, as well as an unrelated clone 
(Masuya et al., 2002). A 67-year-old female patient had 
a chronic myelomonocytic leukemia (CMML) with a 
normal karyotype; she received hydroxyurea. Three 
years later, a refractory anemia with excess of blasts-2 
(RAEB-2) and a t(1;2) was diagnosed. The patient died 
one month later (Storlazzi et al., 2008).  
Refractory anemia with excess of blasts (RAEB) was  
diagnosed in a 69-year-old male patient. The patient 
was still alive 15 months after diagnosis (Horiike et al., 
1988). A T-cell acute lymphoblastic leukemia (T-ALL) 
was found in a 1-year-old child (Mathew et al., 2001). 
Cytogenetics 
Cytogenetics morphological 
In two cases, the t(1;2) was the sole anomaly (Horiike 
et al., 1988; Storlazzi et al., 2008). In contrast, complex 
karyotype were present in the 4 other cases. 
inv(14)(q11q32) was present in the T-ALL case 
(Mathew et al., 2001); del(5q) was found in two cases 
(Roulston et al., 1998; Mauritzson et al., 2002) and 
del(7q) in one case (Masuya et al., 2002). Other 
remarkable anomalies were: t(14;21)(q22;q22) with 
RUNX1 involvement (Roulston et al., 1998), +8, +12, 
+13 appearing during course of the disease (Masuya et 
al., 2002); there was also, in the latter case, an 
unrelated clone with t(11;12)(p15;q13). 
Genes involved and proteins 
Note 
In only one case were the genes involved in the 





Transcription activator; PRDM16 forms a  
transcriptional complex with CEBPB. PRDM16 plays a 
downstream regulatory role in mediating TGFB 
signaling (Bjork et al., 2010). PRDM16 induces brown 
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DNA/RNA 
2 transcript variants; non-coding RNA of unknown 
function. 




PRDM16 (both long and short isoforms) and FLJ42875 
are overexpressed. The sequence on chromosome 2 
upregulating these 2 genes is unknown. 
References 
Horiike S, Taniwaki M, Misawa S, Abe T. Chromosome 
abnormalities and karyotypic evolution in 83 patients with 
myelodysplastic syndrome and predictive value for prognosis. 
Cancer. 1988 Sep 15;62(6):1129-38 
Roulston D, Espinosa R 3rd, Nucifora G, Larson RA, Le Beau 
MM, Rowley JD. CBFA2(AML1) translocations with novel 
partner chromosomes in myeloid leukemias: association with 
prior therapy. Blood. 1998 Oct 15;92(8):2879-85 
Mathew S, Rao PH, Dalton J, Downing JR, Raimondi SC. 
Multicolor spectral karyotyping identifies novel translocations in 
childhood acute lymphoblastic leukemia. Leukemia. 2001 
Mar;15(3):468-72 
Masuya M, Katayama N, Inagaki K, Miwa H, Hoshino N, 
Miyashita H, Suzuki H, Araki H, Mitani H, Nishii K, Kageyama 
S, Minami N, Shiku H. Two independent clones in 
myelodysplastic syndrome following treatment of acute myeloid 
leukemia. Int J Hematol. 2002 Feb;75(2):182-6 
Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, 
Mikoczy Z, Björk J, Strömberg U, Nilsson PG, Mitelman F, 
Hagmar L, Johansson B. Pooled analysis of clinical and 
cytogenetic features in treatment-related and de novo adult 
acute myeloid leukemia and myelodysplastic syndromes based 
on a consecutive series of 761 patients analyzed 1976-1993 
and on 5098 unselected cases reported in the literature 1974-
2001. Leukemia. 2002 Dec;16(12):2366-78 
Storlazzi CT, Albano F, Guastadisegni MC, Impera L, 
Mühlematter D, Meyer-Monard S, Wuillemin W, Rocchi M, 
Jotterand M. Upregulation of MEL1 and FLJ42875 genes by 
position effect resulting from a t(1;2)(p36;p21) occurring during 
evolution of chronic myelomonocytic leukemia. Blood Cells Mol 
Dis. 2008 May-Jun;40(3):452-5 
Kajimura S, Seale P, Kubota K, Lunsford E, Frangioni JV, Gygi 
SP, Spiegelman BM. Initiation of myoblast to brown fat switch 
by a PRDM16-C/EBP-beta transcriptional complex. Nature. 
2009 Aug 27;460(7259):1154-8 
Bjork BC, Turbe-Doan A, Prysak M, Herron BJ, Beier DR. 
Prdm16 is required for normal palatogenesis in mice. Hum Mol 
Genet. 2010 Mar 1;19(5):774-89 
This article should be referenced as such: 
Huret JL. t(1;2)(p36;p21). Atlas Genet Cytogenet Oncol 
Haematol. 2011; 15(1):80-81. 
